These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 28109638)
1. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638 [TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909 [TBL] [Abstract][Full Text] [Related]
3. [A case of myasthenia gravis and myositis induced by pembrolizumab]. Noda T; Kageyama H; Miura M; Tamura T; Ito H Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124 [TBL] [Abstract][Full Text] [Related]
4. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Nguyen BH; Kuo J; Budiman A; Christie H; Ali S Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019 [TBL] [Abstract][Full Text] [Related]
7. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Puwanant A; Isfort M; Lacomis D; Živković SA Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612 [TBL] [Abstract][Full Text] [Related]
8. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report. Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-induced myasthenia gravis: A fatal case report. March KL; Samarin MJ; Sodhi A; Owens RE J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928 [TBL] [Abstract][Full Text] [Related]
10. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Lau KH; Kumar A; Yang IH; Nowak RJ Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302 [TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis exacerbation associated with pembrolizumab. Zhu J; Li Y Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533 [No Abstract] [Full Text] [Related]
12. Myositis as a neuromuscular complication of immune checkpoint inhibitors. Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy. Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313 [TBL] [Abstract][Full Text] [Related]
16. [A case of myasthenia gravis developed during pembrolizumab administration, suggesting an excitation-contraction connection disorder]. Fukazawa R; Takezawa H; Tsuji Y; Noto Y; Banba M; Fujii A Rinsho Shinkeigaku; 2020 Jan; 60(1):37-40. PubMed ID: 31852868 [TBL] [Abstract][Full Text] [Related]
17. [An autopsy case of nivolumab-induced myasthenia gravis and myositis]. Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711 [TBL] [Abstract][Full Text] [Related]
18. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report. Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673 [TBL] [Abstract][Full Text] [Related]